YD Bio Secures RI and PA Lab Licenses, Extends Coverage to 46 States
YDES•YD Bio’s affiliate EG BioMed US obtained Rhode Island clinical genetics and Pennsylvania clinical chemistry/hematology licenses on May 13 and June 9, 2026, expanding its CLIA-certified, CAP-accredited Bothell lab’s operating footprint to 46 states plus D.C. This expansion broadens patient access for its DNA methylation early cancer detection tests.
1. License Approvals in Rhode Island and Pennsylvania
On May 13 and June 9, 2026, EG BioMed US secured Rhode Island clinical genetics and Pennsylvania clinical chemistry and hematology licenses for its CLIA-certified, CAP-accredited Bothell laboratory (CLIA #50D2316600). These approvals mark the addition of two highly regulated jurisdictions to the lab’s authorized operating categories.
2. Expanded Geographic Footprint and Patient Access
The newly added licenses extend the laboratory’s commercial reach to 46 states plus Washington, D.C., enabling broader access to blood-based DNA methylation tests for pancreatic, colorectal, breast and liver cancers. This geographic expansion supports the company’s objective to scale early cancer detection services across the United States.
3. Strategic Role of the Laboratory Platform
YD Bio views its clinical laboratory not as a cost center but as a strategic engine for real-world molecular data accumulation. Each new state license accelerates the collection of high-quality biomarker analytics that underpin its AI-driven cancer detection platform.
4. Future Outlook and Integration Plans
The company anticipates completing its merger with EG BioMed later in 2026, which would further integrate diagnostics capabilities and regulatory infrastructure. Future license expansions could target the remaining U.S. jurisdictions to achieve nationwide coverage.
